Self-harm is a major cause of morbidity in bipolar disorder (BPD),
1 and drug treatments that reduce suicidal and nonsuicidal self-harm could improve quality of life for individuals with BPD and their families.
2 Furthermore, individuals who self-harm have a substantially increased suicide risk.
3 Bipolar disorder is associated with an annual risk of suicidal acts that is 10 times that of the general population
4 and a lifetime risk of suicide that is almost 15 times greater.
5 Randomized clinical trials of maintenance medication show that drugs like lithium, valproate sodium, olanzapine, and quetiapine fumarate can stabilize mood.
6,7 However, balancing the relative benefits and potential risks of these medications is not straightforward, and potential drug effects on self-harm have been underexamined in this regard.